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Abstract
Background: Recently, biomarkers have been suggested to be incorporated into diagnostic criteria for Alzheimer’s
disease (AD). Regarding disease-specific brain amyloid-beta deposition these comprise low amyloid-beta 1–42 in
cerebrospinal fluid (CSF) and positive positron emission tomography (PET) amyloid imaging, while neuronal
degeneration is evidenced by high total and phosphorylated tau levels in CSF (t-/p-tau), regional hypometabolism
([18F]fluorodeoxyglucose PET, FDG-PET) and characteristic atrophy-patterns (magnetic resonance imaging, MRI).
Case presentation: Here we present a case of clinically and biomarker supported AD (CSF t-/p-tau, MRI, FDG-PET)
in a 59-year-old Caucasian man in whom indicators of amyloid-beta deposition dissociated between CSF
parameters and the respective PET imaging.
Conclusions: Such cases highlight the necessity to better understand potential dissociations between PET and CSF
data for amyloid-beta biomarkers, because they are currently considered interchangeably valid with regard to in-
vivo evidence for AD pathology. This is more important since amyloid deposition markers can be considered a very
first prognostic indicator of imminent AD, prior to neurodegenerative biomarkers and cognitive symptoms. The
case illustrates the need for further longitudinal data on potential dissociations of AD biomarkers to devise
recommendations for their better prognostic and diagnostic interpretation in the future.
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Background
Recently, biomarkers have been suggested to be incorpo-
rated into diagnostic criteria for Alzheimer’s disease (AD)
[1, 2]. Evidence for amyloid-beta protein deposition in the
brain is provided by low amyloid-beta 1–42 in cerebro-
spinal fluid (CSF) and positive positron emission tomog-
raphy (PET) amyloid imaging. For downstream neuronal
injury and degeneration elevated total tau (t-tau) and
phosphorylated tau (p-tau) levels in CSF, decreased
[18F]fluorodeoxyglucose uptake on PET (FDG-PET) in
temporoparietal and posterior cingulate cortices, and atro-
phy in temporal and medial parietal cortices on structural
magnetic resonance imaging (MRI) have been established
to yield a high diagnostic precision [2]. Biomarkers for
brain amyloid-beta deposition may be considered espe-
cially important since they provide very early in-vivo evi-
dence of imminent Alzheimer’s pathology, beside proven
AD autosomal dominant mutations in relevant genes such
as presenilin and amyloid precursor protein.
Amyloid PET imaging detects amyloid-beta plaques
with high accuracy as shown in several clinical trials [3].
Accordingly, three [18F]-labeled amyloid-beta-targeting
radiotracers have been approved by the Food and Drug
Administration and the European Medicines Agency.
However, introduction of amyloid-beta PET imaging into
everyday clinical practice requires validation also in the
diagnostic process of single patients to allow personalized
evidence-based medicine. Beyond large scale trials, poten-
tial inconsistencies between different disease-specific bio-
markers in a single patient, as shown here, require
guidelines for clinical practice.
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A 59-year-old Caucasian man presented with progressive
cognitive decline in the memory domain since 18 months.
Memory impairments were relevant in everyday life and
during his work in a garage. Furthermore, he reported
problems in dual task management. Cognition was inves-
tigated in several domains (for references see [4–6]): the
test battery of the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD plus, including Mini Mental
State test, MMST) for global cognitive functioning, the
Bayer Activities of Daily Living (B-ADL) scale for daily life
functioning, subtests of the Testbatterie zur Aufmerksam-
keitsprüfung (TAP) for alertness and divided attention,
the Behavioral Assessment of the Dysexecutive Syndrome
(BADS) for executive functions, and subtests of the
Wechsler Memory Scale (WMS-IV logical memory and
visual reproduction) to assess memory functions. Behav-
ioral impairments were investigated with the Neuro-
psychiatric Inventory (NPI), as well as the Apathy
Evaluation Scale (AES).
Comprehensive neuropsychological testing revealed def-
icits mainly in learning and memory (CERAD wordlist
learning total/recall z = −2.09/−1.99; figures copying/recall
z = 0.81/−3.65; WMS-IV logical memory immediate recall/
delayed recall/recognition percentile rank < 1/<1/2, visual
reproduction immediate recall/delayed recall/recognition
percentile rank = 5/1/2), in attention (CERAD trail making
test A/B z = −2.46/−1,40; TAP tonic/phasic alertness per-
centile rank = 10/4) and executive functions (CERAD
phonematic/semantic fluency z = 0.18/−1.17; BADS action
programme, key search, zoo profile score = 4/4,3/4,0/4).
Executive functions were mainly impaired due to deficits
in encoding complex instructions, while planning and
error monitoring seemed fairly normal. The MMSE score
was 26/30, which indicates mild cognitive impairment
(MCI). Note that the B-ADL scale excluded severe impair-
ments in activities of daily living as assessed by the
patient’s spouse, although the patient had to quit work
due to severe memory deficits, which interfered with his
highly responsible job. The NPI identified only minor, un-
specific behavioral symptoms in the domains depression,
apathy, and irritability/lability ruling out behavioral variant
frontotemporal dementia (score 1 for each domain, total
score 3) [7]. This was confirmed by scores below cut-off in
the AES. Progression of cognitive dysfunction was based
on subjective evaluation by the patient and his relatives
(wife and daughter). A neuropsychological screening three
months before our comprehensive examination showed
comparable results.
Biomarker assessment
As recommended by the National Institute on Aging-
Alzheimer’s Association [2], clinical testing was
supplemented by biomarker investigations for brain
amyloid-beta protein deposition (amyloid PET imaging
using [18F]florbetaben as an amyloid imaging biomarker,
amyloid-beta 1–42 levels in CSF), and for neuronal de-
generation/injury (t-/p-tau in CSF, structural MRI and
FDG-PET).
As illustrated in Fig. 1, structural MR imaging revealed
hippocampal (Scheltens score 4) and parietal atrophy.
MRI revealed multiple small non-confluent white matter
lesions indicating only mild small vessel disease, but no
Fig. 1 Imaging biomarkers for Alzheimer’s disease. Atrophy was
evident in magnetic resonance imaging (MRI) in temporal/
hippocampal regions in T1 (a) and T2 (b) sequence, and in parietal
cortex in T1 (c). Single white matter lesions were detected in fast
fluid-attenuated inversion recovery (FLAIR) images (d). Amyloid
positron emission tomography (PET) with [18F]florbetaben did not
show specific binding in the neocortical gray matter (e), although
hypometabolism was detected in bilateral parietotemporal and
posterior cingluate cortices with [18F]fluorodeoxyglucose-PET (f).
Finally, we evaluated statistical deviation of tracer uptake from a
normal control group including 94 (amyloid) or 25 (glucose) normal
subjects with the Hermes Brass Software. Z score map of the
[18F]florbetaben PET (g) did not show relevant (z score > 2.5) cortical
tracer uptake increase, whereas the z score map of [18F]fluorodeoxy-
glucose-PET (h) showed relevant (z score > 2.5) tracer uptake
reduction in bilateral parietotemporal regions and posterior
cingulate cortices
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other pathology. CSF biomarkers showed a typical AD
pattern with decreased amyloid-beta 1–42 (345.3 pg/ml;
reference value > 450), increased p-tau (78.7 pg/ml;
reference value < 61), and slightly elevated t-tau
(439.9 pg/ml; borderline value 300–450, pathological >
450). All other CSF-parameters were normal apart
from a mildly increased total protein (547.7 mg/l; ref-
erence value 200–500). Surprisingly, amyloid PET with
[18F]florbetaben did not show elevated tracer uptake
throughout the whole gray matter (Fig. 1). The com-
posite standard uptake value ratio - an established
measure of the mean brain amyloid load [8, 9] -
equalled 1.09 (threshold < 1.39) thus not suggesting an
AD pathology. All other biomarkers supported AD in-
cluding a highly AD-typical pattern for glucose hypo-
metabolism (FDG-PET) in bilateral parietotemporal
and posterior cingulate cortex as illustrated in Fig. 1
[10]. The apolipoprotein E status was E3/E3.
The comprehensive clinical and paraclinical examin-
ation confirmed the diagnosis of AD, supported by bio-
markers (CSF, MRI, FDG-PET) [1, 2], although the
investigations revealed a dissociation between PET and
CSF data for brain amyloid-beta deposition. Other meta-
bolic, traumatic and medical causes of cognitive symp-
toms were ruled out.
Conclusions
Biomarkers indicating amyloid-beta deposition in the
brain have been suggested to yield in-vivo evidence of
Alzheimer’s pathology. Here, we show that biomarkers
for amyloid-beta deposition can be dissociated between
PET and CSF. Notably all clinical and further biomarkers
(CSF t-tau and p-tau, MRI, FDG-PET) supported the
diagnosis of AD. In line with our finding, a recent study
[11] including amyloid-beta PET and CSF levels has
shown a considerable dissociation between [18F]florbeta-
pir PET and amyloid-beta 1–42 in CSF in 20 out of 374
subjects (5.3 %) ranging from normal to MCI and AD
(103, 249, 22 subjects, respectively). The 13 participants
showing a dissociation with abnormal [18F]florbetapir
PET vs. normal CSF amyloid-beta 1–42 were normal
control subjects or early MCI cases. The remaining
seven participants with more substantial cognitive defi-
cits and higher CSF t-tau (one AD, four late MCI, one
early MCI, one normal) showed the reverse dissociation
with normal [18F]florbetapir PET vs. abnormal CSF
amyloid-beta 1–42. The latter pattern is confirmed in
the here reported case of late MCI/early dementia due
to AD and, though it may be rare in AD (one in 22 AD
patients, accordingly approximately 4.5 % in the above
mentioned study), it is of relevance to the individualized
counselling of patients. With respect to Landau et al.’s
[11] and our findings one might hypothesize specific dis-
sociations in the course of AD with positive amyloid
PET and normal CSF amyloid-beta 1–42 in early MCI
and a reverse pattern with decreased CSF amyloid-beta
1–42 and normal amyloid PET in late MCI or clinically
evident AD (dementia stage), although this assumption
is based on a small number of cases warranting caution
with regard to generalization.
Generally, Landau et al. [11] reported a robust nega-
tive correlation between both biomarkers for brain amyl-
oid deposition as shown by [18F]florbetapir PET
retention and CSF amyloid-beta 1–42 levels in their AD
cohort. This correlation was more robust than correla-
tions with t-tau or p-tau. Such a negative correlation
was also shown in another study with [11C]Pittsburgh
compound B (PIB) PET retention and levels of CSF
amyloid-beta 1–42 [12]. The latter study additionally re-
vealed a significant negative correlation between CSF
amyloid-beta 1–42 levels and [11C]PIB PET retention in
parietal (including the precuneus) and temporal cortices,
the posterior cingulate, frontal and primary visual cortex.
Interestingly, such a correlation was not established for
t-tau or p-tau. Both effects in this study [12] were only
observed when patients with AD (37) and its prestage
MCI (21) were pooled, highlighting potential effects of
the comparatively low sample size.
In conclusion, our case report shows that biomarkers
for amyloid-beta deposition can be dissociated between
PET and CSF in clinically and biomarker supported
otherwise typical AD. This finding is of special relevance
because amyloid biomarkers have been suggested to be
incorporated into diagnostic criteria for AD [1, 2]. Un-
derstanding potential dissociations between PET and
CSF data for amyloid-beta biomarkers is of particular
relevance, because these biomarkers are currently con-
sidered to interchangeably yield very early in-vivo evi-
dence of AD pathology prior to neurodegenerative
biomarkers and cognitive symptoms [13]. Accordingly,
further studies and longitudinal data are warranted to inter-
pret such dissociated AD biomarker patterns and develop
recommendations on how to cope with these discrepancies
in diagnostic procedures in the future.
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